In a response to recent research conducted by Flatiron scientists and oncologists regarding how the expansion of eligibility criteria can impact the diversity of trial participants, Flatiron's Vice President of Research Oncology reflects on the progress we still need to make on ensuring diversity among clinical trial participants
Other videos from this series:
-
Research Background: Trial eligibility criteria and diversity among patients with advanced NSCLC
-
Research Goal: Trial eligibility criteria and diversity among patients with advanced NSCLC
-
Research Methodology: Trial eligibility criteria and diversity among patients with advanced NSCLC
-
Research Findings: Trial eligibility criteria and diversity among patients with advanced NSCLC
-
Research Learnings: Trial eligibility criteria and diversity among patients with advanced NSCLC
-
Research Learnings: How can sponsors balance eligibilty criteria and diversity goals?
-
Research Learnings: Why is diversity in clinical trials, essential?
-
What are future expectations for ensuring diversity in clinical trials?
-
What can sponsors do to enable more diversity in clinical trial?
Learn more about our clinical research solutions
Interested in seeing how Flatiron is bridging the gap between care and research?
